BurdenADBissonnetteRNavariniAA, et alSpesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase IIb, dose-finding study. Dermatol Ther (Heidelb). 2023;13(10):2279-2297. doi:10.1007/s13555-023-01002-1
2.
AlaviAPrensEKimballAB, et alProof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled clinical trial. Br J Dermatol. 2024;191(4):508-518.
3.
SugiuraKFujitaHKomineMYamanakaKAkiyamaM.The role of interleukin-36 in health and disease states. J Eur Acad Dermatol Venereol. 2024;38(10):1910-1925.
4.
XiaolingYChaoWWenmingWFengLHongzhongJ.Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis. Clin Exp Dermatol. 2019;44(1):52-57. doi:10.1111/ced.13689
5.
Meier-SchiesserBFeldmeyerLJankovicD, et alCulprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis. J Invest Dermatol. 2019;139(4):848-858. doi:10.1016/j.jid.2018.10.023
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
